Cargando…

Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients

The aim of this retrospective cohort study was to compare safety, efficacy and rates and reasons of discontinuation of the 3 currently approved integrase strand transfer inhibitors (INSTIs) elvitegravir (EVG), dolutegravir (DTG), and raltegravir (RAL) in HIV-infected treatment-naïve and -experienced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brehm, Thomas Theo, Franz, Marleen, Hüfner, Anja, Hertling, Sandra, Schmiedel, Stefan, Degen, Olaf, Kreuels, Benno, Schulze zur Wiesch, Julian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708907/ https://www.ncbi.nlm.nih.gov/pubmed/31393378 http://dx.doi.org/10.1097/MD.0000000000016721

Ejemplares similares

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
por: Castagna, Antonella, et al.
Publicado: (2014)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection
por: Wehmeyer, Malte H, et al.
Publicado: (2014)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
por: Beisel, Claudia, et al.
Publicado: (2014)

Malaria in the Time of COVID-19: Do Not Miss the Real Cause of Illness
por: Jochum, Johannes, et al.
Publicado: (2021)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
por: Restelli, Umberto, et al.
Publicado: (2017)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022)

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
por: Oliveira, Maureen, et al.
Publicado: (2018)

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
por: Eron, Joseph J., et al.
Publicado: (2013)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
por: Despiégel, Nicolas, et al.
Publicado: (2015)

Inversed Ratio of CD39/CD73 Expression on γδ T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease Progression
por: Kolbe, Katharina, et al.
Publicado: (2022)

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
por: Doyle, Tomas, et al.
Publicado: (2015)

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
por: Jacobs, Tom G., et al.
Publicado: (2022)

Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review
por: Townsend, Claire L., et al.
Publicado: (2022)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: M. Llibre, Josep, et al.
Publicado: (2016)

549. Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen
por: Gibson, Amanda, et al.
Publicado: (2018)

Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens
por: Smith, Robert A., et al.
Publicado: (2012)

Clinical characteristics and comparison of longitudinal qPCR results from different specimen types in a cohort of ambulatory and hospitalized patients infected with monkeypox virus.
por: Nörz, Dominik, et al.
Publicado: (2022)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: Llibre, Josep M., et al.
Publicado: (2016)

Similar Durability of Two Single Tablet Regimens, Dolutegravir/Abacavir/Lamivudine and Elvitegravir/Cobicistat/Tenofovir/Emtricitabine: Single Center Experience
por: Chin, Bum Sik, et al.
Publicado: (2020)

Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review
por: Naccarato, Mark J., et al.
Publicado: (2018)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
por: Quercia, Romina, et al.
Publicado: (2015)

Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016
por: Perez Valero, Ignacio, et al.
Publicado: (2020)

Longitudinal SARS-CoV-2 Seroprevalence among Employees in Outpatient Care Services in Hamburg
por: Schablon, Anja, et al.
Publicado: (2023)

Salvage therapy with raltegravir in a 3-month-old infant
por: Brolund, AB, et al.
Publicado: (2010)

Screening for Monkeypox Infection in Asymptomatic High-Risk-Behaviour Men Having Sex with Men (MSM)
por: Pestel, Julia, et al.
Publicado: (2022)

Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study
por: Perez Stachowski, Javier, et al.
Publicado: (2022)

Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir
por: Patiño Escarcina, Jesús Enrique, et al.
Publicado: (2023)

Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis
por: Wittner, Melanie, et al.
Publicado: (2019)

Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020
por: Brehm, Thomas Theo, et al.
Publicado: (2021)

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015)

Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)
por: Schäfer, Guido, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u5c31vqtvdkhq2sn91opfvn38t